Overall, results from the phase III Valor trial testing Lyme disease vaccine PF-07307405 “strengthen confidence” in the candidate, according to partners Pfizer Inc. and Valneva SE, with the big pharma ...

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the abnormal accumulation of α-synuclein, a ...

Facing increasing competition to PI3Kα inhibitor Piqray (alpelisib) in breast cancer, Novartis AG looks to bolster its ...

In what the U.S. FDA has dubbed a milestone move toward fewer animal studies in drug development, the agency published a draft guidance to help sponsors validate new approach methodologies that can ...

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and ...

With top-line pivotal data with gene therapy RGX-202 for Duchenne muscular dystrophy (DMD) due in the next quarter, Regenxbio ...

Further weight loss details are yet to come this year, but Eli Lilly and Co. scored positive top-line results in Transcend-T2D-1, a phase III trial evaluating the efficacy and safety of retatrutide, ...

Congruence Therapeutics Inc. has closed a $39.5 million financing to advance into its portfolio of small-molecule correctors ...

Otsuka Pharmaceutical Co. Ltd. reaped positive results from an open-label phase II study of repinatrabit (JNT-517) in ...

A recent study aimed to de novo design mini-protein inhibitors that specifically block the membrane insertion of soluble complement C9. This work, led by researchers from Shandong Second Medical ...

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, ...